Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

PubWeight™: 2.62‹?› | Rank: Top 1%

🔗 View Article (PMID 7574461)

Published in Ann Neurol on October 01, 1995

Authors

R Motter1, C Vigo-Pelfrey, D Kholodenko, R Barbour, K Johnson-Wood, D Galasko, L Chang, B Miller, C Clark, R Green

Author Affiliations

1: Athena Neurosciences, Inc, South San Francisco, CA 94080, USA.

Articles citing this

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60

Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43

Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41

The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem (2008) 2.35

Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx (2004) 2.02

CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83

Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. Neuroimage (2012) 1.71

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol (2013) 1.63

Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage (2009) 1.63

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2007) 1.61

Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J Neurosci (2011) 1.53

Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol Cell Neurosci (2007) 1.48

Surface-based TBM boosts power to detect disease effects on the brain: an N=804 ADNI study. Neuroimage (2011) 1.41

Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37

The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm (Vienna) (2006) 1.33

Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One (2011) 1.32

Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 1.26

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 1.25

New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement (2013) 1.22

The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system. EMBO Mol Med (2009) 1.20

Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron (2014) 1.19

CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol Aging (2011) 1.16

Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline. Neurobiol Aging (2010) 1.10

Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (Vienna) (2009) 1.10

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers. Clin Chem (2013) 1.04

The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci (2015) 1.02

Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta (2008) 1.01

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol (2014) 1.00

Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement Geriatr Cogn Disord (2012) 0.99

Precision Medicine: Clarity for the Complexity of Dementia. Am J Pathol (2015) 0.97

Alzheimer's disease: diagnostics, prognostics and the road to prevention. EPMA J (2010) 0.96

Structural and mechanistic commonalities of amyloid-β and the prion protein. Prion (2011) 0.95

Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94

CSF Biomarkers for Alzheimer's Disease Diagnosis. Int J Alzheimers Dis (2010) 0.94

Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Mol Med (1996) 0.94

Ocular manifestations of Alzheimer's disease in animal models. Int J Alzheimers Dis (2012) 0.94

Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study. BMC Neurol (2010) 0.93

Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD). Mol Neurodegener (2011) 0.92

β-amyloid dynamics in human plasma. Arch Neurol (2012) 0.91

Cell-derived soluble oligomers of human amyloid-beta peptides disturb cellular homeostasis and induce apoptosis in primary hippocampal neurons. J Neural Transm (Vienna) (2009) 0.91

CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease. Mol Med (2011) 0.90

The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases. Neurol Sci (2009) 0.90

Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. PLoS One (2013) 0.90

Progranulin protein levels are differently regulated in plasma and CSF. Neurology (2014) 0.90

Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiol Aging (2010) 0.89

Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol (2009) 0.89

Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed) (2013) 0.89

CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. J Neural Transm (Vienna) (2006) 0.88

Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J Neural Transm (Vienna) (2007) 0.87

Mild cognitive impairment: historical development and summary of research. Dialogues Clin Neurosci (2004) 0.86

A chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization. PLoS One (2012) 0.86

A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci (2016) 0.86

Regenerable and simultaneous surface plasmon resonance detection of aβ(1-40) and aβ(1-42) peptides in cerebrospinal fluids with signal amplification by streptavidin conjugated to an N-terminus-specific antibody. Anal Chem (2010) 0.84

Biomarkers predicting Alzheimer's disease in cognitively normal aging. J Clin Neurol (2011) 0.84

Defective PITRM1 mitochondrial peptidase is associated with Aβ amyloidotic neurodegeneration. EMBO Mol Med (2015) 0.83

Saliency modulates global perception in simultanagnosia. Exp Brain Res (2010) 0.82

Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. Front Neurol (2015) 0.81

Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis. PLoS One (2015) 0.81

Cerebrospinal fluid and blood biomarkers in Alzheimer's disease. World J Psychiatry (2011) 0.81

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J Neural Transm (Vienna) (2012) 0.81

Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. Yale J Biol Med (2016) 0.81

Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. J Neural Transm (Vienna) (2001) 0.80

Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (1997) 0.80

Synergistic interactions between Alzheimer's Aβ40 and Aβ42 on the surface of primary neurons revealed by single molecule microscopy. PLoS One (2013) 0.79

Biomarkers in Alzheimer's disease. Front Neurol (2011) 0.79

Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol (2014) 0.79

Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer's Disease. Clin Psychopharmacol Neurosci (2011) 0.79

Anatomic and clinical pathology of cognitive impairment and dementia. J Alzheimers Dis (2013) 0.79

CSF tau and β-amyloid as biomarkers for mild cognitive impairment. Dialogues Clin Neurosci (2004) 0.79

Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains. Clin Proteomics (2013) 0.79

Different CSF β-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. J Neural Transm (Vienna) (2011) 0.78

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. Alzheimers Dement (Amst) (2015) 0.77

PUTATIVE CSF PROTEIN BIOMARKER CANDIDATES FOR AMNESTIC MILD COGNITIVE IMPAIRMENT. Transl Neurosci (2010) 0.77

Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease. Mov Disord (2015) 0.77

What does it mean to be 'amyloid-positive'? Brain (2015) 0.77

Cerebrospinal fluid β-amyloid 1-42 correlates with rate of progression in Alzheimer's disease. J Neural Transm (Vienna) (2012) 0.77

Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition. Neurobiol Aging (2014) 0.77

Conformation-dependent oligomers in cerebrospinal fluid of presymptomatic familial Alzheimer's disease mutation carriers. Dement Geriatr Cogn Dis Extra (2012) 0.77

Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Front Neurol (2015) 0.76

An overview of biomarkers in Alzheimer's disease. Ann Indian Acad Neurol (2010) 0.76

Neurochemical biomarkers in Alzheimer's disease and related disorders. Ther Adv Neurol Disord (2012) 0.76

From model system to clinical medicine: pathophysiologic links of common proteinopathies. Alzheimers Res Ther (2010) 0.76

Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease. Int J Alzheimers Dis (2010) 0.75

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Emergence of the Solution to an Important Unmet Need. EJIFCC (2013) 0.75

Fear and Uncertainty Do Not Influence Reported Willingness to Undergo Lumbar Punctures in a U.S. Multi-Cultural Cohort. Front Aging Neurosci (2017) 0.75

Genomic and Proteomic Biomarker Discovery in Neurological Disease. Biomark Insights (2008) 0.75

Cross-View Neuroimage Pattern Analysis in Alzheimer's Disease Staging. Front Aging Neurosci (2016) 0.75

Comparison of two commercial enzyme-linked immunosorbent assays for cerebrospinal fluid measurement of amyloid β1-42 and total tau. Transl Neurosci (2013) 0.75

Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review. Neuropsychol Rev (2015) 0.75

Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects. Neurobiol Aging (2013) 0.75

Applying new research criteria for diagnosis of early Alzheimer's disease: sex and intelligence matter. Int J Alzheimers Dis (2009) 0.75

Alterations of the volatile metabolome in mouse models of Alzheimer's disease. Sci Rep (2016) 0.75

Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside. Diagnostics (Basel) (2017) 0.75

Articles by these authors

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology (1989) 16.83

The use of statins: a case of misleading priorities? BMJ (1997) 13.35

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33

Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96

High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46

Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89

The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ (2007) 7.74

Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51

Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature (1992) 7.16

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 7.02

A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Genes Dev (1998) 6.74

An improved rosetting assay for detection of human T lymphocytes. J Immunol Methods (1974) 6.54

Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51

Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77

Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A (1999) 5.75

Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A (1997) 4.92

A base pair between tRNA and 23S rRNA in the peptidyl transferase centre of the ribosome. Nature (1995) 4.59

Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol (2001) 4.54

School-based programs to reduce sexual risk behaviors: a review of effectiveness. Public Health Rep (1994) 4.50

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45

The guanosine binding site of the Tetrahymena ribozyme. Nature (1989) 4.43

Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry (2001) 4.37

Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31

The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27

Growth response of Nitrosomonas europaea to amino acids. J Bacteriol (1967) 4.26

Electrographic seizures and periodic discharges after intracerebral hemorrhage. Neurology (2007) 4.22

Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry (2001) 4.13

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10

Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA (1995) 4.02

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest (2001) 3.86

Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem (1996) 3.84

The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology (1990) 3.79

Aircraft and road traffic noise and children's cognition and health: a cross-national study. Lancet (2005) 3.64

Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg (2001) 3.49

School-based screening for tuberculous infection. A cost-benefit analysis. JAMA (1995) 3.47

Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci (2001) 3.46

Are amyotrophic lateral sclerosis patients cognitively normal? Neurology (2003) 3.21

Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol (1995) 3.18

Neighborhood poverty as a predictor of intimate partner violence among White, Black, and Hispanic couples in the United States: a multilevel analysis. Ann Epidemiol (2000) 3.17

Coronary artery ligation in anesthetized rats as a method for the production of experimental dysrhythmias and for the determination of infarct size. J Pharmacol Methods (1980) 3.10

Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology (2003) 3.07

Recovered memories of childhood sexual abuse. Implications for clinical practice. Br J Psychiatry (1998) 3.02

Hidden from view: violent deaths among pregnant women in the District of Columbia, 1988-1996. J Midwifery Womens Health (2001) 2.95

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86

Diversity of Conus neuropeptides. Science (1990) 2.78

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet (2001) 2.76

JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunity (1999) 2.74

Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther (2005) 2.71

Breast cancer among black and white women in the 1980s. Changing patterns in the United States by race, age, and extent of disease. Cancer (1993) 2.70

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67

Postoperative wound infection: a computer analysis. Br J Surg (1971) 2.67

Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66

Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA (1991) 2.64

Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev (1999) 2.56

Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol (2001) 2.56

Isolation and characterization of new fission yeast cytokinesis mutants. Genetics (1998) 2.51

Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest (1984) 2.43

Olfactory deficits in schizophrenia. Biol Psychiatry (1988) 2.38

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology (2011) 2.35

Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem (1997) 2.33

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33

Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res (2002) 2.32

Haptoglobin phenotype and diabetic nephropathy. Diabetologia (2001) 2.27

Airway smooth muscle, tidal stretches, and dynamically determined contractile states. Am J Respir Crit Care Med (1997) 2.26

Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology (2000) 2.26

Comparison of a generic (SF-36) and a disease specific (WOMAC) (Western Ontario and McMaster Universities Osteoarthritis Index) instrument in the measurement of outcomes after knee replacement surgery. J Rheumatol (1995) 2.23

Drinking histories of self-identified lifetime abstainers and occasional drinkers: findings from the 1958 British Birth Cohort Study. Alcohol Alcohol (2006) 2.22

V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2001) 2.19

Effect of mixed culture on Nitrosomonas europaea simulated by uptake and utilization of pyruvate. J Bacteriol (1966) 2.19

Base-pairing between 23S rRNA and tRNA in the ribosomal A site. Mol Cell (1999) 2.19

Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology (2005) 2.18

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther (2014) 2.17

Serodiagnosis of Lyme borreliosis by western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi. J Clin Microbiol (1992) 2.17

Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16

Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet (2007) 2.15

Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem (2001) 2.14

Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem (1994) 2.14

Deformation tensor morphometry of semantic dementia with quantitative validation. Neuroimage (2004) 2.14

Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A (1998) 2.13

Rehabilitation of hemiparesis after stroke with a mirror. Lancet (1999) 2.13

The mechanism of lysis in phage T4-infected cells. Virology (1967) 2.12

Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst (2001) 2.12

Distortion correction and robust tensor estimation for MR diffusion imaging. Med Image Anal (2002) 2.09

Current concepts in the diagnosis of cobalamin deficiency. Neurology (1995) 2.08